BioLineRx Begins Phase 1/2a Study of GLIX1 to Combat Glioblastoma BioLineRx has initiated a Phase 1/2a clinical trial for GLIX1, a promising new treatment for glioblastoma, targeting DNA damage response in cancer cells.

BioLineRx Begins Phase 1/2a Study of GLIX1 to Combat Glioblastoma #Israel #Tel_Aviv #BioLineRx #Glioblastoma #GLIX1

BioLineRx Reports 2025 Financial Performance and Strategic Developments for Future Clinical Trials BioLineRx is set to initiate a Phase 1/2a trial for GLIX1 in glioblastoma, highlighting significant financial results and ongoing research in cancer therapy.

BioLineRx Reports 2025 Financial Performance and Strategic Developments for Future Clinical Trials #Israel #Tel_Aviv #oncology #BioLineRx #GLIX1

BioLineRx's Q3 2025 Financial Disclosure and Corporate Strategy Revamping BioLineRx Ltd. announces its Q3 2025 financial results, alongside an update on corporate initiatives, including joint venture developments.

BioLineRx's Q3 2025 Financial Disclosure and Corporate Strategy Revamping #Israel #Tel_Aviv #BioLineRx #motixafortide #GLIX1

BioLineRx and Hemispherian Form Joint Venture to Advance GLIX1 for Glioblastoma Treatment BioLineRx Ltd. and Hemispherian AS have established a joint venture to develop GLIX1, a novel oral treatment for glioblastoma and other cancers, pending FDA approval.

BioLineRx and Hemispherian Form Joint Venture to Advance GLIX1 for Glioblastoma Treatment #Israel #Tel_Aviv #BioLineRx #GLIX1 #Hemispherian

BioLineRx's Q2 2025 Financial Results: A Corporate Update on Pipeline Expansion BioLineRx Ltd. shares its financial results for Q2 2025, highlighting advancements in pipeline expansion and promising opportunities in oncology.

BioLineRx's Q2 2025 Financial Results: A Corporate Update on Pipeline Expansion #biopharmaceuticals #oncology #BioLineRx

BioLineRx Presents Groundbreaking Data on Pancreatic Cancer Treatment at ASCO 2025 Annual Meeting BioLineRx Ltd. reveals promising data from its combination therapy trial for pancreatic cancer, showcasing a significant advance in treatment options for this challenging disease.

BioLineRx Presents Groundbreaking Data on Pancreatic Cancer Treatment at ASCO 2025 Annual Meeting #Israel #Tel_Aviv #BioLineRx #pancreatic_cancer #motixafortide

#BioLineRx ( #BLRX) shines in Q1 2025! Advancing APHEXDA® for stem cell mobilization and expanding oncology pipeline with promising trials. Strong financials with $40.2M in cash fuel growth. Exciting times for biotech innovation!

prismmarketview.com/biolinerx-hi...

BioLineRx Delivers Promising Progress in Q1 2025 Financial Results and Corporate Developments BioLineRx has reported its Q1 2025 financial results, showcasing significant advancements in drug development and corporate strategies in oncology and rare diseases.

BioLineRx Delivers Promising Progress in Q1 2025 Financial Results and Corporate Developments #Israel #Tel_Aviv #BioLineRx #APHEXDA #motixafortide

BioLineRx Announces Strong Financial Results for 2024 and Strategic Corporate Developments BioLineRx Ltd. reported impressive 2024 financial results highlighting strategic partnerships and enhanced focus on oncology and rare diseases.

BioLineRx Announces Strong Financial Results for 2024 and Strategic Corporate Developments #Israel #Tel_Aviv #oncology #BioLineRx #APHEXDA

BioLineRx Shares Strategic Outlook Amidst Bolder Future Goals BioLineRx provides an in-depth letter to shareholders detailing its future strategies and financial outlook following a significant licensing agreement.

BioLineRx Shares Strategic Outlook Amidst Bolder Future Goals #Israel #Tel_Aviv #oncology #BioLineRx #APHEXDA

BioLineRx Adjusts American Depositary Shares Ratio to Support Nasdaq Compliance and Growth BioLineRx announces a significant adjustment in the ratio of American Depositary Shares to ordinary shares, aiming to enhance compliance with Nasdaq listing standards.

BioLineRx Adjusts American Depositary Shares Ratio to Support Nasdaq Compliance and Growth #Israel #Tel_Aviv #oncology #BioLineRx #Biopharma

BioLineRx Secures $10 Million for Advancing Life-Changing Therapies in Oncology BioLineRx has announced a $10 million direct offering to support its drug development efforts in oncology and rare diseases. This funding will enhance their pipeline significantly.

BioLineRx Secures $10 Million for Advancing Life-Changing Therapies in Oncology #biopharmaceuticals #Israel #Tel_Aviv #BioLineRx #DrugDevelopment

BioLineRx Announces Positive Developments in Financials and Strategic Directions for 2024 BioLineRx shares insights into its third-quarter financial results and strategic initiatives aimed at enhancing shareholder value for 2024.

BioLineRx Announces Positive Developments in Financials and Strategic Directions for 2024 #healthcare #Israel #Tel_Aviv #BioLineRx #APHEXDA